Abstract. The mouse embryonic stem cell test (mEST) is used to assess the embryotoxicity of drug candidates by evaluating the effects on the cardiac differentiation of stem cells. However, thalidomide embryotoxicity has not yet been reported using the mEST. To detect the effects of thalidomide, we used human induced pluripotent stem cells (hiPSCs) instead of mouse embryonic stem cells, and assessed three endpoints: the inhibition of cardiac differentiation, the cytotoxicity to hiPSCs, and the cytotoxicity to human dermal fibroblasts, according to the mEST. From these data (IC 50 values), the embryotoxicity was classified into one of three different classes based on the mEST and our criteria. Valproate was used as a positive control and ascorbic acid was used as a negative control, and their effects were assessed. Similar to valproate, thalidomide was classified as a Class 2 agent, with weak embryotoxicity, by the mEST criteria, and was classified as Category 3 embryotoxic based on our criteria. Ascorbic acid was classified as a Class 1 / Category 1, non-embryotoxic agent, based on both criteria. Thalidomide embryotoxicity was detected in the embryonic stem cell test based on hiPSCs. This test system is thus considered to have a much greater predictive ability than the mEST.
Introduction
Developmental toxicity, including embryotoxicity and teratogenicity (an irreversible malformation), is a crucial type of toxicity that affects offspring and needs to be assessed during the nonclinical drug development process. However, in vivo reproductive and developmental studies to assess the developmental toxicity of drug candidates is rarely carried out before clinical trials of the drugs due to the use of a large number of animals, the long experimental period, and the high cost, so that pregnant females and females who may become pregnant are excluded from phase 1 clinical trials.
Three in vitro developmental toxicity tests are currently used to assess the embryotoxicity of drug candidates and chemicals. They include the wholeembryo culture test, rat limb bud micromass test, and the mouse embryonic stem cell test (mEST), and these tests have already been validated by the European Center for the Validation of Alternative Methods (ECVAM) (1) . In particular, the mEST, which uses cardiac differentiation as an indicator of the evaluation, is easy to perform in comparison to the in vivo nonclinical studies and has the advantage of not requiring the use of experimental pregnant/non-pregnant animals, The mEST has been adopted by a number of pharmaceutical companies as a tool to assess the embryotoxicity of drug candidates at an early stage in drug development.
Thalidomide is known to have adverse teratogenic effects on human fetuses (2, 3) . However, the adverse effects of thalidomide are difficult to detect in in vivo reproductive and developmental studies in rodents (4, 5) . This may be due to species barrier-related differences between rodents and humans. The effects of thalidomide (6, 7) . Therefore, we tried to study the teratogenic potential of thalidomide using hiPSCs instead of mouse ES cells. We also assessed in the present study the effects of sodium valproate and ascorbic acid, which have previously been confirmed to have teratogenic effects and no effects in rodent studies (8 -10) , as a positive and negative control, respectively.
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Materials and Methods
The present study was conducted following the company policy on the research ethics review committee of our institution.
Test and differentiation-inducing drugs
Thalidomide, sodium valproate and recombinant human activin-A (activin-A) were purchased from Wako Pure Chemicals (Osaka); ascorbic acid, from Nacalai Tesque (Kyoto); recombinant human Wnt-3a (Wnt-3a) and recombinant human noggin (noggin), from R&D Systems (Minneapolis, MN, USA); and recombinant human bone morphogenetic protein-4 (BMP-4) from HumanZyme (Chicago, IL, USA). Thalidomide was dissolved in dimethylsulfoxide (Dojindo, Kumamoto) and diluted in appropriate medium, as described below. Sodium valproate and ascorbic acid were dissolved in medium and used after filter sterilization (0.20 mm).
Cell culture medium
Modified Tenneille serum replacer 1 (mTeSR 
Cells
The hiPSCs were derived from human bone marrow mononuclear cells which were purchased from AllCells (Emeryville, CA, USA) (11) . Human dermal fibroblasts isolated from adult normal skin which were obtained from ScienCell Research Laboratories (Carlsbad, CA, USA).
Test procedure
Differentiation test: Cardiac differentiation was assessed using the modified mEST method. The hiPSCs maintained in feeder-free condition was harvested by 1 mg/mL dispase (STEMCELL Technologies). The cells were suspended in AggreWell TM medium supplemented with Y-27632 (10 mM), a Rho-associated protein kinase (ROCK) inhibitor, seeded on AggreWell TM 800 plates (STEMCELL Technologies), and incubated at 37°C, 5% CO 2 with saturated humidity. One to two days later, embryonic bodies (hiPSCs aggregates) were formed, and the medium was replaced with B27-DMEM/F12. Embryonic bodies were transferred to Nunc ® ultralow-cell-binding 24-well culture plates (Thermo Fisher Scientific, Rochester, NY, USA) and the test drug or vehicle was added to each well except for the control well. Subsequently, activin-A (100 ng/mL), Wnt-3a (100 ng/mL), and BMP-4 (100 ng/mL) were added to all wells. Twenty-four hours later, the medium was replaced with B27-DMEM/F12 supplemented with noggin (300 ng/mL) or noggin and the test drug or vehicle, and thereafter, the medium was replaced daily with fresh medium containing the same components for 3 days. Embryonic bodies were transferred to 96-well culture plates (one embryonic body/well, 24-well/group) coated with 0.1 w/v% StemSure TM gelatin (Wako Pure Chemicals), and the media were replaced with FBS-DMEM/F12. The beating cardiomyocytes were observed morphologically under a microscope every day.
Cytotoxicity tests: Cytotoxicities of the drugs to the hiPSCs and human dermal fibroblasts were assessed using the mEST method (13) with some modifications. The cytotoxicity was determined using the Cell meter TM colorimetric cell cytotoxicity assay kit (AAT Bioquest, Sunnyvale, CA, USA), which is based on resazurin as an indicator of mitochondrial function, according to the manufacturer's manual. The hiPSCs were harvested by 1 mg/mL dispase, and the human dermal fibroblasts were detached by 0.05% trypsin-EDTA (1%) (Life Technologies). Each cell was suspended in medium and seeded into Nunc ® 96-well optical-bottom plates (Thermo Fisher Scientific), coated with matrigel (BD Biosciences, Bedford, MA, USA) for hiPSCs and poly-l-lysine (Trevigen, Gaithersburg, MD, USA) for human dermal fibroblasts, at 1000 cells/0.1 mL per well, and then incubated at 37°C, 5% CO 2 with saturated humidity. Two hours later, medium with the test drug (two-fold of the final concentration) was added at 0.1 mL/well, with 3 or 4 wells being treated at each concentration. The medium with drug was refreshed daily for 4 days. The medium with drug was then discarded, and 0.1 mL of medium was added to all wells. One hour later, 0.02 mL of Cell meter TM assay solution was added to all wells. The absorbance change at 570 and 605 nm was monitored using a microplate reader (SpectraMax ® M3, Molecular Devices, Sunnyvale, CA, USA), and the cell viability in each well was determined as the absorbance ratio of 570 nm to 605 nm. The results were calculated as a relative percentage to the control cells.
The hiPSCs were cultured in mTeSR TM 1, and the human dermal fibroblasts were cultured in dermal fibroblast growth medium. The sensitivities to the drugs were not significantly different based on the data when the cells were treated for 4 or 10 days. Therefore, we selected the treatment period of 4 days in order to simplify the experimental procedures in this assay.
Data analyses
Calculation of IC 50 values: The IC 50 value of the agent with regard to inhibiting the differentiation of embryonic body cells into beating cardiomyocytes, as well as the IC 50 value (IC 50 PS) for hiPSCs and the IC 50 value (IC 50 F) for human dermal fibroblasts, were calculated by the logit method using the SAS software program ver. 9.2 (SAS Institute Japan, Tokyo).
Classification of test drugs
mEST criteria: Each function value (I, II, and III) was calculated by individual linear discriminant functions based on the IC 50 , IC 50 F, and IC 50 PS values, as shown in Table 1 . To classify the embryotoxic potential of the test drugs into one of three different classes, the values of each function were compared and classified, as shown in Table 1 .
Our new criteria: In order to classify the embryotoxic potential of the test drugs into one of three different categories, the IC 50 , IC 50 F, and IC 50 PS values were compared and classified, as shown in Table 2 . We established our own criteria, because the mEST criteria are thought to be affected by the intensity of the test drug activity, including cytotoxicity. In order to eliminate the affect of the intensity of the test drug activity, our criteria was made to compare relative toxicity to embryonic cells and other cells (maternal). We believe that using our own criteria to judge the three IC 50 values may thus enable us to more appropriately evaluate the embryotoxic potential.
Results
All of the embryonic bodies (hiPSCs aggregates) differentiated into beating cardiomyocytes in the control group of all tests.
Sodium valproate
Sodium valproate inhibited the differentiation of embryonic bodies into beating cardiomyocytes with an IC 50 value of 125 mg/mL (Fig. 1A , Table 4 ). This drug decreased the viability of human dermal fibroblasts and hiPSCs at IC 50 F value of 300 mg/mL and at IC 50 PS value of 121 mg/mL, respectively (Fig. 1A , Table 4 ).
In the mEST criteria shown in Table 1 , the values of functions I, II, and III as calculated from the IC 50 , IC 50 F, and IC 50 SP values were 3.6, 6.0, and −2.1, respectively (Table 5) . From the comparison of the data of these functions, II > I and II > III, sodium valproate was classified as a weak embryotoxin of class 2 (Table 6 ). Based on our original criteria shown in Table 2 (Table 6) .
Sodium valproate was validated to have developmental toxicity according to this test system based on the hiPSCs.
Ascorbic acid
Ascorbic acid inhibited the differentiation of embryonic bodies into beating cardiomyocytes with an IC 50 value of 622 mg/mL (Fig. 1B, Table 4 ). This drug decreased the viability of human dermal fibroblasts and hiPSCs at IC 50 F value of 567 mg/mL and at IC 50 PS value of 658 mg/mL, respectively (Fig. 1B, Table 4 ).
Based on the mEST criteria shown in Table 1 , the values of functions I, II, and III calculated from IC 50 , IC 50 F, and IC 50 SP values were 11.4, 10.2, and −3.2, respectively (Table 5) . From the comparison of the data of these functions, I > II and I > III, ascorbic acid was classified as non-embryotoxic and was considered to be a class 1 agent (Table 6 ). Based on our original criteria shown in Table 2 , ascorbic acid was also classified as non-embryotoxic, category 1, according to the comparison of IC 50 values: IC 50 F < IC 50 and IC 50 F < IC 50 PS (Table 6) .
Ascorbic acid was validated not to have any developmental toxicity according to this test system based on the hiPSCs.
Thalidomide
Thalidomide inhibited the differentiation of embryonic bodies into beating cardiomyocytes with an IC 50 value of 117 mg/mL (Fig. 1C , Table 4 ). This drug decreased the viability of human dermal fibroblasts and hiPSCs at IC 50 F value of 578 mg/mL and at IC 50 PS value of 207 mg/mL, respectively (Fig. 1C, Table 4 ).
In the mEST criteria shown in Table 1 , the values of functions I, II, and III calculated from IC 50 , IC 50 F, and IC 50 SP values were 4.9, 7.1, and −1.8, respectively (Table 5) . From the comparison of the data of these functions: II > I and II > III, so thalidomide was classified as a weak embryotoxin of class 2 (Table 6 ). Based on our own original criteria shown in Table 2 (Table 6) .
Thalidomide embryotoxicity was detected in this test system. 
Discussion
The developmental toxicity of thalidomide, in addition to sodium valproate, was detected in the present study, while ascorbic acid showed negative results. The positive results of thalidomide have not been reported in the mEST using cardiac differentiation as a marker of toxicity. The mouse embryonic stem cells differentiate spontaneously into cardiomyocytes in the presence of fetal bovine serum, and the removal of murine leukemia inhibitory factor maintains them in an undifferentiated state (13) . In the same culture conditions, hiPSCs hardly differentiate into cardiomyocytes (data was not shown). Therefore, it is suggested that the cardiac differentiation pathway is different between mice and humans. The adverse effects of thalidomide have been shown to be caused by the inhibition of cereblon, a component of the ubiquitin ligase that is important for the expression of an essential regulator of limb development. However, zebra fish and chickens were used in this study because the adverse effects of thalidomide are difficult to detect in rodents (4, 5, 14) . For these reasons, the in vitro developmental toxicity test based on hiPSCs would be a useful tool to assess the developmental toxicity of candidate drugs in humans. We considered that the in vitro developmental toxicity test based on the hiPSCs may have much greater predictive ability than that based on mouse ES cells because of the potential differences in some developmental pathways in humans compared to mice.
In the present study, similar to the positive control drug (sodium valproate), thalidomide was classified as a Class 2 agent (weak embryotoxic potential), not as a Class 3 (strong embryotoxic potential) agent, by the mEST criteria, despite the fact that both are categorized as Category X agents, indicating that the use of the agent should be avoided in pregnant females and those who may become pregnant, as established by the United States Food and Drug Administration (FDA) and the Australian Drug Evaluation Committee (ADEC). One reason for the different classification of the mEST criteria may be caused by the intensity of the drug activity, including cytotoxicity, because all IC 50 values of Class 3 agents tend to be lower than those of Class 1 agents. It has been suggested that the results of the mEST classification would be obtained due to the weak The brackets contain the 95% confidence interval (mg/mL). hiPSCs: human induced pluripotent stem cells, IC50: 50% inhibition of the differentiation of embryonic bodies into beating cardiomyocytes, IC50F: 50% inhibition of the viability of human or mouse fibroblasts, IC50PS: 50% inhibition of the viability of human induced pluripotent stem cells, IC50ES: 50% inhibition of the viability of mouse embryonic stem cells. inhibitory activities of test drugs on cardiac development and cell viabilities. On the other hand, our proposed criteria is independent of the intensity of inhibitory activity on cardiac development and cell viabilities, from the published mEST data, and the detailed drug data prepared by the pharmaceutical company.
We considered that the effects of the drug on human dermal fibroblasts would more closely mimic maternal conditions and that the hiPSCs would reflect the embryonic state. When either the cardiac differentiation endpoint or the hiPSCs endpoint is lower than the human dermal fibroblast endpoint, the test drug is judged to have the suspected embryotoxic potential (e.g., to cause irreversible structural malformations, the death of embryos, and others). When both endpoints are lower than the human dermal fibroblast endpoint, the test drug is judged to have embryotoxic potential. Then, based on the benefits/risks for patients, the continuation of drug development is assessed. Based on our original criteria, both thalidomide and valproate were classified as Category 3 agents, with embryotoxicity, including a teratogenic potential. The ability to predict the embryotoxic potential using our criteria was almost identical to that noted in the clinical data. This suggests that using our criteria in addition to the mEST criteria increases the predictive performance of the mEST classification.
In the present study, the true extent of developmental toxicity of thalidomide in humans was detected by using our in vitro test system based on the hiPSCs for the first time. Further studies using more reference drugs and the hiPSCs of other cell lines are needed in order to demonstrate the usefulness of the in vitro developmental toxicity test based on the hiPSCs. This humanized test system may be able to more accurately predict the developmental toxicity of drug candidates at an early stage in drug development by combining the mEST criteria with the criteria proposed in this study.
